L. Adams
Gastroenterology · 2005–2021
A researcher in the Science corpus: 10 papers; trusts 0 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Whom L. Adams trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts L. Adams overall
- Z. Younossi
- V. Ratziu
- R. Loomba
- G. Targher
- Q. Anstee
- Megan H. Bair-Merritt
- H. B. EL‐SERAG
- M. Rinella
- C. Day
- Christopher D. Byrne
Papers from L. Adams's perspective
Ordered by how strongly the researchers L. Adams trusts endorse each paper. Same corpus, a different order for every researcher.
- ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (Hepatology)
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis (Nature Reviews Gastroenterology &Hepatology)
- Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study (Hepatology)
- Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. (Nature Medicine)
- EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (Obesity Facts)
- Of markets and rights: Discourse in the 2008 and 2013 Global Action Plan for the Prevention and Control of Noncommunicable Diseases
- 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The… (Journal of the American College of Cardiology)
- Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. (Clinical Gastroenterology and Hepatology)
- Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta‐analysis (Journal of Gastroenterology and Hepatology)
- The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota (Hepatology)
Their papers
- Advancing the global public health agenda for NAFLD: a consensus statement (2021) — 631 citations
- A new definition for metabolic associated fatty liver disease: an international expert consensus statement. (2020) — 3,051 citations
- The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease (2020) — 732 citations
- Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. (2018) — 707 citations
- Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases (2017) — 1,030 citations
- Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease (2015) — 2,665 citations
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007) — 3,034 citations
- The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. (2005) — 948 citations
- The natural history of nonalcoholic fatty liver disease: a population-based cohort study. (2005) — 2,924 citations
- Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. (2005) — 735 citations